BRAF and melanoma: In particular, vemurafenib, trametinib, dabrafenib, and other inhibitors of the BRAF–MEK signaling pathway that is hyperactive in melanoma patients bearing BRAFV600 mutations have proven superior to traditional chemotherapy in terms of both antitumor activity and clinical outcome (11–13).